Glioma Diagnosis and Treatment

Gliomas are primary brain tumors arising from glial cells, with glioblastoma representing the most aggressive form and one of the deadliest cancers in adults. Over the past two decades, molecular profiling has transformed how these tumors are classified and treated: mutations in the IDH gene and methylation of the MGMT promoter, for instance, now directly inform prognosis and predict whether patients are likely to benefit from the chemotherapy agent temozolomide combined with radiotherapy. Medulloblastoma, a distinct tumor more common in children, has similarly been reorganized into biologically meaningful subtypes through genetic analysis, illustrating a broader shift from purely anatomical diagnosis toward molecular classification across the entire glioma spectrum. Central open questions include how to overcome the near-universal resistance that glioblastoma eventually develops to standard treatment, and whether emerging immunotherapy approaches can be made effective against tumors that have evolved sophisticated mechanisms to evade immune recognition within the brain.

Works

156,585

Total citations

2,457,255

Keywords

GlioblastomaTemozolomideIDH MutationRadiotherapyMolecular ClassificationMGMT Promoter Methylation